HomeCurrent Issue
Current Issue
January 2024 - Volume 3 - 1
Editorial
18 September 2024•
Consideration of initial steps to implementation of prostate cancer screening following the EU recommendationPatricia Fitzpatrick
22 August 2024•
Determining fracture risk in patients exposed to immune checkpoint inhibitors: the time is nowJanet Helen Roberts
29 August 2024•
Do shortcuts leave older patients short changed? The UK TOASTIE studyRichard Simcock, Nicolò Matteo Luca Battisti
21 August 2024•
Unlocking the predictive power of imaging biomarkers: predicting immune checkpoint therapy response in non-small cell lung cancer through baseline tumour vessel perfusionsSuraiya Dubash, Yat Tsang
12 August 2024•
Geriatric oncology in LMICs: it is time to matureAmol Akhade, Haydee Verduzco-Aguirre, Bishal Gyawali
7 August 2024•
Recall of ibrutinib and issues with therapeutic approvalColton Lipfert, Myung Sun Kim, Alyson Haslam, Vinay K Prasad
6 August 2024•
Deciphering chemotherapy resistance: a novel apoptosis protein profile analysis in stage II colorectal cancerZixiang Li, Leilei Fu
11 July 2024•
Availability of quality-of-life results for clinical decisions: an evolving scenarioMassimo Di Maio
11 July 2024•
Potential of neutrophil-to-eosinophil ratio as a new prognostic tool for patients with advanced renal cell carcinoma receiving first-line immuno-oncology combinationsKosuke Takemura, Daniel Y C Heng
8 July 2024•
Research priorities to improve cancer care for people with intellectual disabilities across the cancer continuumMaarten Cuypers, Deborah Cairns, Kathryn A Robb
5 July 2024•
Does the regional use of intensive chemotherapy impact the outcome of adults with AML?Corentin Orvain
13 June 2024•
Addressing the hidden toxicities of cancer: a call to action for clinicians, researchers and clinical trialistsRick Bangs
15 May 2024•
Careful take-off by the EQ-5D-5L tool in lung cancer: fly little one, fly!Kurt G Tournoy
30 April 2024•
Uncovering the role of mismatch repair deficiency and microsatellite instability in urothelial carcinomaFilippo Ghelardi, Patrizia Giannatempo, Filippo Pietrantonio
18 April 2024•
In pursuit of parity: addressing gender disparities in global cancer researchKristina Jenei
13 March 2024•
Embracing rapid learning in radiotherapy: feasible and acceptable with stakeholder corroborationClaire Poole
13 February 2024•
Identifying the deficits in cancer care for people with intellectual disabilitiesMaarten Cuypers, Deborah Cairns, Kathryn A Robb
10 February 2024•
Cervical cancer screening using tests that provide same-day results: a study of test accuracyLynette Denny
1 February 2024•
Time, location and function of hypoxia-inducible factors are critical to therapeutic tumour responseLaure Marignol, Christopher William Pugh
1 February 2024•
Machine learning predicted fast progression after initiation of immune checkpoint inhibitors in advanced non-small cell lung cancerYu Yang Soon, Teng Hwee Tan, Chee Khoon Lee, Martin Stockler
Original research
2 November 2024•
From prediction to practice: mitigating bias and data shift in machine-learning models for chemotherapy-induced organ dysfunction across unseen cancersMatthew Watson, Pinkie Chambers, Luke Steventon, James Harmsworth King, Angelo Ercia, Heather Shaw, Noura Al Moubayed
18 September 2024•
Associations between socioeconomic factors and PSA testing in a population-based organised testing programme and routine healthcare: a register-based study of 50-year-old menEmil Järbur, Erik Holmberg, Thomas Björk-Eriksson, Ola Bratt, Rebecka Arnsrud Godtman
29 August 2024•
UK national observational cohort study investigating Tolerance of Anti-cancer Systemic Therapy in the Elderly: the TOASTIE studyMark A Baxter, Michael Rowe, Kieran Zucker, Adam L Peters, Maria Rohan, Alexandra Marsh, Abigail L Gee, Gemma Quesne, Jonny Heseltine, Rachel Prichard, Deborah Scott, Conor O'Neill, Clair Brunner, Joni Howells, Veronica Conteh, Avinash Aujayeb, Xiangfei Yan, Lisa J Rodgers, Sally Martin, Helen Dearden, , J Grech, L Hannington, S McInerney, S Kingdon, H Ali, L Eastlake, S Park, R Bryce, D Parslow, V Cope, J Hamilton, G Clements, N Aziz, J Platt, R Heywood
22 August 2024•
Increase in major osteoporotic fractures after therapy with immune checkpoint inhibitorsCarrie Ye, Bo Zhao, William D Leslie, Juan Ignacio Ruiz, Hui Zhao, Noha Abdel-Wahab, Maria E Suarez-Almazor
21 August 2024•
Baseline tumour vessel perfusion as a non-invasive predictive biomarker for immune checkpoint therapy in non-small-cell lung cancerZhenhua Liu, Ke Ma, Qingzhu Jia, Yunpeng Yang, Peng Fan, Ying Wang, Junhui Wang, Jiya Sun, Liansai Sun, Hongtai Shi, Liang Sun, Bo Zhu, Wei Xu, Li Zhang, Rakesh K. Jain, Songbing Qin, Yuhui Huang
14 August 2024•
As bleak as it sounds? Analysing trends in oncology clinical trial initiation in the UK from 2010 to 2022Alexander David VanHelene, Matthew J Hadfield, Dario Trapani, Jeremy Lyle Warner, Mark P Lythgoe
13 August 2024•
Prospective comparative study of quality of life in patients with bladder cancer undergoing cystectomy with ileal conduit or bladder preservationVedang Murthy, Sheetal R Kashid, Mahendra Pal, Alvina Vadassery, Priyamvada Maitre, Amandeep Arora, Pallavi Singh, Amit Joshi, Ganesh Bakshi, Gagan Prakash
12 August 2024•
Under-representation of older Indian persons with cancer in clinical trialsVanita Noronha, Vijay Patil, Nandini Menon, Manali Kolkur, Zoya Peelay, Minit Shah, Vijayalakshmi Mathrudev, Srushti Shah, Kavita Nawale, Nita S Nair, Anant Ramaswamy, Vikas Ostwal, Sarbani Ghosh-Laskar, Jai Prakash Agarwal, Pankaj Chaturvedi, Supriya Chopra, Vedang Murthy, Sheila N Myatra, Jigeeshu Divatia, Vikram Gota, Sudeep Gupta, Vikram Chaudhari, Sabita Jiwnani, Shailesh V Shrikhande, Richa Vaish, Devendra Chaukar, Shivakumar Thiagarajan, Sudhir Nair, Anil D'Cruz, Amey Oak, Rohini Hawaladar, Oindrila Roy Chowdhury, Shripad Banavali, Rajendra Badwe, Kumar Prabhash
12 August 2024•
Cancer burden across the South Asian Association for Regional Cooperation in 2022Urvish Jain, Faraan Rahim, Bhav Jain, Abhinav Komanduri, Aditya Arkalgud, Cameron John Sabet, Alessandro Hammond, Phub Tshering, Tej A Patel, Bhawna Sirohi, Pankaj Jain, Shah Zeb Khan, Sanjeeva Gunasekera, Ramila Shilpakar, Zabihullah Stanikzai, Arman Reza Chowdhury, Nishwant Swami, Edward Christopher Dee, Bishal Gyawali
8 August 2024•
Association of pre-existing cardiovascular disease with administration of fluoropyrimidine chemotherapy in patients with gastrointestinal malignanciesAderonke Temilade Abiodun, Chengsheng Ju, Catherine A Welch, Jennifer Lai, Freya Tyrer, Pinkie Chambers, Lizz Paley, Sally Vernon, John Deanfield, Mark de Belder, Mark Rutherford, Paul C Lambert, Sarah Slater, Kai Keen Shiu, Li Wei, Michael D Peake, , David Adlam, Charlotte Manisty, , David Adlam, Mick Peake, John Deanfield, Lucy Elliss-Brookes, Mark de Belder, Sarah Darby, Chris Gale, Mike Hawkins, Paul Lambert, Alexander Lyon, Jem Rashbass, Raoul Reulen, Alistair Ring, Mark Rutherford, Michael Sweeting, Adam Timmis, Sally Vernon, Paul Charlton, Sally Jeans, Alison Fielding, Andy Deutsch, James Chal, Akosua Donkor, Nadeem Fazal, Anil Gunesh, Andrew Harrison, Lizz Paley, Brian Shand, Sally Vernon, Jennifer Lai, Abbas Khushnood, Andrew Goodwin, Peter Ludman, Theresa McDonagh, Francis Murgatroyd, Clive Weston
8 August 2024•
Vitamin B6 status and chronic chemotherapy-induced peripheral neuropathy: a prospective cohort study among patients with non-metastatic colorectal cancer receiving oxaliplatin-based chemotherapyLisanne Renting, Nienke R K Zwart, Per Magne Ueland, Adrian McCann, Arve Ulvik, Henk K van Halteren, Floor J E Lubberman, Renate M Winkels, Ellen Kampman, Dieuwertje E Kok
7 August 2024•
Choosing Wisely in oncology: are guidelines effective at preventing unnecessary diagnostics? The example of surveillance positron emission tomography for patients with localised colorectal cancerDaniel A Goldstein, Roi Tschernichovsky, Talish Razi, Keren Filosof, Idan Menashe, Ronen Arbel, Doron Netzer
6 August 2024•
Preconsultation compassion video to reduce anxiety among patients referred to a cancer centre: a randomised control trialChristine Winn, Generosa Grana, Anthony Mazzarelli, Andrea Nicholson, Kristine Mykulowycz, Chidinma Obiakor, Alicia Bair, Stephen Trzeciak, Brian Roberts
6 August 2024•
Integrated multiplex analysis of cell death regulators in stage II colorectal cancer suggests patients with ‘persister’ cell profiles fail to benefit from adjuvant chemotherapySanghee Cho, Elizabeth McDonough, John Graf, Jinru Shia, Canan Firat, Nil Urganci, Christine Surrette, Andreas Lindner, Manuela Salvucci, Anna Matveeva, Batuhan Kisakol, Anthony O’Grady, Mohammadreza Azimi, John P Burke, Deborah A McNamara, Simon McDade, Daniel B Longley, Jochen HM Prehn, Fiona Ginty
30 July 2024•
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancerChad Tang, Genevieve P Hartley, Coline Couillault, Ying Yuan, Heather Lin, Courtney Nicholas, Anupallavi Srinivasamani, James Dai, Ecaterina E Ileana Dumbrava, Siqing Fu, Daniel D Karp, Aung Naing, Sarina A Piha-Paul, Jordi Rodon Ahnert, Shubham Pant, Vivek Subbiah, Timonthy A Yap, Apostolia M Tsimberidou, Paola Guerrero, Sarah Dhebat, Theresa Proia, Michael A Curran, David S Hong
29 July 2024•
Surgical management of skull base chordomas and chondrosarcomas: insights from a national cohort studyLaurence J Glancz, Cathal John Hannan, Alexandros Vyziotis, Gillian M Potter, Rekha Siripurapu, Raj K Bhalla, Scott A Rutherford, Andrew Thomas King, Charlotte Hammerbeck-Ward, Adrian Crellin, Shermaine Pan, Rovel Colaco, Gillian A Whitfield, Omar N Pathmanaban
20 July 2024•
Novel machine learning algorithm in risk prediction model for pan-cancer risk: application in a large prospective cohortXifeng Wu, Huakang Tu, Qingfeng Hu, Shan Pou Tsai, David Ta-Wei Chu, Chi-Pang Wen
18 July 2024•
Assessing the rates of false-positive ovarian cancer screenings and surgical interventions associated with screening tools: a systematic reviewSierra M Silverwood, Grant Backer, Annie Galloway, Katrina Reid, Anna Jeter, Margo Harrison
11 July 2024•
Health-related quality of life outcomes reporting associated with FDA approvals in haematology and oncologyMedhavi Gupta, Othman Salim Akhtar, Bhavyaa Bahl, Angel Mier-Hicks, Kristopher Attwood, Kayla Catalfamo, Bishal Gyawali, Pallawi Torka
5 July 2024•
Regional disparities in the use of intensive chemotherapy for AML in the Netherlands: does it influence survival?Z L Rana Kaplan, Nikki van Leeuwen, David van Klaveren, Otto Visser, Eduardus F M Posthuma, Danielle van Lammeren-Venema, Tjeerd J F Snijders, Catharina H M J van Elssen, Anna van Rhenen, Peter A von dem Borne, Nicole M A Blijlevens, Jan J Cornelissen, Marc H G P Raaijmakers, Arjan A van de Loosdrecht, Gerwin Huls, Valery E P P Lemmens, Hester F Lingsma, Avinash G Dinmohamed
12 June 2024•
Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trialMatthew Tucker, Yu-Wei Chen, Martin H Voss, Bradley A McGregor, Mehmet A Bilen, Marc-Oliver Grimm, Paul Nathan, Christian Kollmannsberger, Yoshihiko Tomita, Bo Huang, Robert Amezquita, Mariangela Mariani, Alessandra di Pietro, Brian Rini
30 May 2024•
Blood-based DNA methylation markers for lung cancer predictionJustina Ucheojor Onwuka, Florence Guida, Ryan Langdon, Mikael Johansson, Gianluca Severi, Roger L Milne, Pierre-Antoine Dugué, Melissa C Southey, Paolo Vineis, Torkjel Sandanger, Therese Haugdahl Nøst, Marc Chadeau-Hyam, Caroline Relton, Hilary A. Robbins, Matthew Suderman, Mattias Johansson
21 May 2024•
Patterns of cytotoxic T-cell densities in immunogenic endometrial cancers reveal a potential mechanism for differences in immunotherapy efficacyNeil Ryan, Mark Glaire, Thomas Walker, Natalja ter Haar, Marieke Ijsselsteijn, James Bolton, Noel de Miranda, Gareth Evans, David N Church, Tjalling Bosse, Emma Crosbie
15 May 2024•
Exploring the value of routinely collected data on EQ-5D-5L and other electronic patient-reported outcome measures as prognostic factors in adults with advanced non-small cell lung cancer receiving immunotherapyKuan Liao, David C Wong, Fabio Gomes, Corinne Faivre-Finn, Laura Moliner, Matthew Sperrin, Janelle Yorke, Sabine N van der Veer
9 May 2024•
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumoursAung Naing, Kyriakos P Papadopoulos, Michael J Pishvaian, Osama Rahma, Glenn J Hanna, Elena Garralda, Omar Saavedra, Sven Gogov, Howard Kallender, LuLu Cheng, Michael Smith, Xuejun Chen, Emil Kuriakose, Todd Bauer
8 May 2024•
Defining national research priorities for prostate cancer in Zambia: using the Delphi process for comprehensive cancer policy setting in sub-Saharan AfricaDorothy Chilambe Lombe, Monde Mwamba, Musonda Simwinga, Virginia Bond, Andrew Sentoogo Ssemata, Richard Muhumuza, Janet Seeley, Kennedy Lishimpi, Victor Mapulanga, John Kachimba, Ajay Aggarwal, Susan Msadabwe
30 April 2024•
Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysisElias B A Chandran, Giovanni Maria Iannantuono, Saad O Atiq, Dilara Akbulut, Ninet Sinaii, Nicholas I Simon, Abdul Rouf Banday, Salah Boudjadi, Sandeep Gurram, Amin H Nassar, Jonathan E Rosenberg, Gisela Butera, Min Yuen Teo, Guru Sonpavde, Jonathan A Coleman, Andrea B Apolo
18 April 2024•
Sex and authorship in global cancer researchMiriam Mutebi, Grant Lewison, Deborah Mukherji, Nazik Hammad, Verna Vanderpuye, Erica Liebermann, Winnie K W So, Julie Torode, Richard Sullivan, Ophira Ginsburg
11 April 2024•
Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trialsAlexander D Sherry, Pavlos Msaouel, Timothy A Lin, Joseph Abi Jaoude, Ramez Kouzy, Esther J Beck, Avital M Miller, Adina H Passy, Gabrielle S Kupferman, Eugene J Koay, Clifton David Fuller, Charles R Thomas, Zachary R McCaw, Ethan B Ludmir
8 April 2024•
Characterisation of clinical response and transcriptional profiling of proliferating CD8 T cells in the blood of cancer patients after PD-1 monotherapy or combination therapyRebecca C Obeng, Tahseen H Nasti, Kylee Martens, Peng Li, Annapaola Mariniello, Daniel Y Chang, Christiane S Eberhardt, Donald McGuire, Haydn Kissick, Candace Daugherty, Yuzi Zhang, Andreas Wieland, Zhengjia Chen, Jeffrey M Switchenko, Rathi Pillai, Alice O Kamphorst, Warren J Leonard, Rafi Ahmed, Suresh S Ramalingam
3 April 2024•
Tale of two zones: investigating the clinical outcomes and research gaps in peripheral and transition zone prostate cancer through a systematic review and meta-analysisAmin Ali, Thiraviyam Elumalai, BhanuPrasad Venkatesulu, Lauren Hekman, Hitesh Mistry, Ashwin Sachdeva, Pedro Oliveira, Noel Clarke, Esther Baena, Ananya Choudhury, Robert G Bristow
19 March 2024•
Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trialsBrody Dennis, Chance Bratten, Griffin K Hughes, Andriana M Peña, Ryan McIntire, Chase Ladd, Brooke Gardner, William Nowlin, Reagan Livingston, Jordan Tuia, Alyson Haslam, Vinay Prasad, Matt Vassar
13 March 2024•
Feasibility of implementing a rapid-learning methodology to inform radiotherapy treatments: key professional stakeholders’ viewsArbaz Kapadi, Gareth Price, Corinne Faivre-Finn, Rebecca Holley, Kate Wicks, Kathryn Banfill, Gareth Webster, Kevin Franks, Fiona McDonald, Daniel Johnson, David P French
12 March 2024•
Challenges faced by women oncologists in Africa: a mixed methods studyMiriam Mutebi, Naa Adorkor Aryeetey, Haimanot Kasahun Alemu, Laura Carson, Zainab Mohamed, Zainab Doleeb, Nwamaka Lasebikan, Nazima Jaffer Dharsee, Susan Msadabwe, Doreen Ramogola-Masire, Sitna Mwanzi, Khadija Warfa, Emmanuella Nwachukwu, Edom Seife Woldetsadik, Hirondina Vaz Borges Spencer, Nesrine Chraiet, Matthew Jalink, Reshma Jagsi, Dorothy Chilambe Lombe, Verna Vanderpuye, Nazik Hammad
29 February 2024•
Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid reviewHannah Louise Bromley, Mohini Varughese, Duncan C Gilbert, Peter Hoskin, Ian F Tannock, Kimberley Reeves, Ananya Choudhury
10 February 2024•
Accuracy of screening tests for cervical precancer in women living with HIV in low-resource settings: a paired prospective study in Lusaka, ZambiaKatayoun Taghavi, Misinzo Moono, Mulindi Mwanahamuntu, Marie Roumet, Andreas Limacher, Herbert Kapesa, Thamsanqa Madliwa, Anne Rutjes, Partha Basu, Nicola Low, Albert Manasyan, Julia Bohlius
1 February 2024•
Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapyJian-Guo Zhou, Jie Yang, Haitao Wang, Ada Hang-Heng Wong, Fangya Tan, Xiaofei Chen, Si-Si He, Gang Shen, Yun-Jia Wang, Benjamin Frey, Rainer Fietkau, Markus Hecht, Wenzhao Zhong, Hu Ma, Udo Gaipl
30 January 2024•
Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spendingDaniel A Goldstein, Leonard B Saltz, Gregory R Pond, Ian F Tannock
9 January 2024•
Novel proteomics-based plasma test for early detection of multiple cancers in the general populationBogdan Budnik, Hossein Amirkhani, Mohammad H Forouzanfar, Ashkan Afshin
Review
2 October 2024•
Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and moreTimothée Olivier, Alyson Haslam, Dagney Ochoa, Eduardo Fernandez, Vinay Prasad
10 September 2024•
Circulating tumour cell clusters: isolation, biological significance and therapeutic implicationsYufan Yang, Guanyin Huang, Jingru Lian, Chunhao Long, Boxi Zhao, Xuefei Liu, Binyu Zhang, Weijian Ye, Junhao Chen, Longxiang Du, Zhuofeng Jiang, Jialing Liu, Jianglin Zhang, Chengzhi Hu, Qingfeng Chen, Xin Hong
16 July 2024•
Association between rheumatoid arthritis and risk of radiotherapy toxicity: a systematic reviewNina Liebenberg, Alan McWilliam, Sarah L Kerns, Deborah C Marshall, Catharine M West
31 May 2024•
Implications of hormonal carcinogenesis for transgender and gender-diverse people undergoing gender-affirming hormone therapy: an up-to-date reviewAlberto Giovanni Leone, Stefania Bonadonna, Chiara Cassani, Amelia Barcellini, Marianna Sirico, Barbara Tagliaferri, Stefano Maccarone, Davide Dalu, Lorenzo Ruggieri, Filippo Ghelardi, Matteo Lambertini, Simone Nardin, Rossana Berardi, Nicla La Verde, Francesco Perrone, Saverio Cinieri, Dario Trapani, Filippo Pietrantonio
10 May 2024•
Prospective evaluation of artificial intelligence (AI) applications for use in cancer pathways following diagnosis: a systematic reviewSheba Macheka, Peng Yun Ng, Ophira Ginsburg, Andrew Hope, Richard Sullivan, Ajay Aggarwal
1 March 2024•
HealthCare Access Barrier (HCAB) framework for the barriers to cancer care during conflicts: perspective from IraqKouther Mohsin, Layth Mula-Hussain, Richard Gilson
1 February 2024•
Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunityBrian M Ortmann
17 January 2024•
Repurposing radiosensitising medicines for radiotherapy: an overviewJie Man Low, Gonzalo Rodriguez-Berriguete, Geoff S Higgins
17 January 2024•
Artificial intelligence across oncology specialties: current applications and emerging toolsJohn Kang, Kyle Lafata, Ellen Kim, Christopher Yao, Frank Lin, Tim Rattay, Harsha Nori, Evangelia Katsoulakis, Christoph Ilsuk Lee